Alexander Azoy - 01 Dec 2023 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
01 Dec 2023
Net transactions value
-$4,216
Form type
4
Filing time
05 Dec 2023, 16:28:11 UTC
Previous filing
05 Jul 2023
Next filing
20 Dec 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Sale $4,216 -282 -2.4% $14.95 11,596 01 Dec 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023.
F2 Consists of 282 shares purchased on 11/30/2023 through the Company's Employee Stock Purchase Plan.